SMN2 and proximal spinal muscular atrophy: This is a phase 3, open-label, single-arm, multicenter, ongoing, single-dose intravenous study of AVXS-101, including pre-symptomatic patients up to six weeks of age with an anticipated development of SMA types 1 or 2 with 2 or 3 copies of the SMN2 gene.